Maxim downgraded Immutep (IMMP) to Hold from Buy after the company’s Phase 3 study with Merck (MRK) of eftilagimod alfa in patients in first line non-small cell lung cancer was halted for futility.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Morning News Wrap-Up 3/13/26: Friday’s Biggest Stock Market Stories!
- Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
- Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study
- Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?
- Immutep downgraded to Neutral from Outperform at Baird